Go Viral researchers are investigating oncolytic viruses (OVs)  for therapeutic use in Glioblastoma (GBM).

Therapeutic Use

For the Treatment of Glioblastoma

OVs infect and destroy cancer cells without damaging normal cells and can be injected intra-tumorally to increase efficacy and improve safety. Additionally, OVs promote anti-tumor responses through a dual mechanism of action. OVs both kill cancer cells and activate the immune system by exposure to new antigens.

Glioblastoma (GBM) are of significant interest to our researchers. Below are statistics about this type of brain cancer.

Cases of GBM diagnosed yearly
0
of all brain tumors
0 %
Five year survival rate
0 %
Deaths per year
0

Most aggressive and still incurable brain cancer, despite the availability of newer treatment options.

~50% of adult malignant brain tumors are GBM.

Average global annual incidence is 0.5 – 5 / 100,000 adults.

Most common cause of death among patients with Central Nervous System tumors.

Median age at diagnosis is 64 years.

Median survival is ~15 months with best standard of care (SOC) and a 5-year survival rate <10%.